Retraction Note to: Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies [Mol Biol Rep, (2014), 41, (3925-3933), DOI 10.1007/s11033-014-3260-0];Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: A meta-analysis of 21 cohort studies

Molecular Biology Reports

Volumn 41, Issue 6, 2014, Pages 3925-3933

  Li, Yong Shuang ^a   Xie, Qiang ^a   Yang, Da Ye ^a   Zheng, Yuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; Promoter methylation; RASSF1A

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ASIAN; CANCER TISSUE; CARCINOGENESIS; CAUCASIAN; COHORT ANALYSIS; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; METHYLATION; PROMOTER REGION; RASSF1A GENE; ASIAN CONTINENTAL ANCESTRY GROUP; DNA METHYLATION; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; PATHOLOGY; PROGNOSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84902364411     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-015-3889-3     Document Type: Erratum

References (43)

1. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS (2010) An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2:54ra77. doi:10.1126/scitranslmed.3001338
2. Sherman M (2010) Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30:3-16. doi:10.1055/s-0030-1247128
3. Chuang SC, La Vecchia C, Boffetta P (2009) Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286:9-14. doi:10.1016/j.canlet.2008.10.040
4. Pan H, Fu X, Huang W (2011) Molecular mechanism of liver cancer. Anticancer Agents Med Chem 11:493-499. http://www.ncbi.nlm.nih.gov/pubmed/ 21554201
5. Arzumanyan A, Reis HM, Feitelson MA (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13:123-135. doi:10.1038/nrc3449
6. Liu Y, Chang CC, Marsh GM, Wu F (2012) Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer 48:2125-2136. doi:10.1016/j.ejca.2012.02.009
7. Zhao ZH, Fan YC, Yang Y, Wang K (2013) Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 19:7189-7196. doi:10.3748/wjg.v19.i41. 7189
8. Dratviman-Storobinsky O, Cohen Y, Frenkel S, Merhavi-Shoham E, El SD, Binkovsky N, Pe'er J, Goldenberg-Cohen N (2012) The role of RASSF1A in uveal melanoma. Invest Ophthalmol Vis Sci 53:2611-2619. doi:10.1167/iovs.11-7730
9. Duan C, Liu M, Zhang J, Ma R (2013) Rassf1a: a potential novel therapeutic target against cardiac hypertrophy. Prog Biophys Mol Biol 113:284-288. doi:10.1016/j.pbiomolbio.2013.07.004
10. Yee KS, Grochola L, Hamilton G, Grawenda A, Bond EE, Taubert H, Wurl P, Bond GL et al (2012) A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res 72:2206-2217. doi:10.1158/0008-5472.CAN-11-2906
11. Richter AM, Pfeifer GP, Dammann RH (2009) The rassf proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796:114-128. doi:10.1016/j.bbcan.2009.03.004
12. Gao T, Wang S, He B, Pan Y, Song G, Gu L, Chen L, Nie Z et al (2012) The association of RAS association domain family protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One 7:e48300. doi:10.1371/journal.pone.0048300
13. Xu B, Di J, Wang Z, Han X, Li Z, Luo X, Zheng Q (2013) Quantitative analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its prognostic implications. Biochem Biophys Res Commun 438:324-328. doi:10.1016/j.bbrc.2013.07.070
14. Saelee P, Wongkham S, Chariyalertsak S, Petmitr S, Chuensumran U (2010) Rassf1a promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Asian Pac J Cancer Prev 11:1677-1681. http://www.ncbi.nlm.nih.gov/ pubmed/21338215
15. Lorente A, Mueller W, Urdangarin E, Lazcoz P, Lass U, von Deimling A, Castresana JS (2009) RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTS. Brain Pathol 19:279-292. doi:10.1111/j.1750-3639. 2008.00185.x
16. Wang J, Wang B, Chen X, Bi J (2011) The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 32:411-416. doi:10.1093/carcin/bgq266
17. Feng Q, Stern JE, Hawes SE, Lu H, Jiang M, Kiviat NB (2010) DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 88:287-292. doi:10.1016/j.yexmp.2010. 01.002
18. Honda S, Haruta M, Sugawara W, Sasaki F, Ohira M, Matsunaga T, Yamaoka H, Horie H et al (2008) The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 123:1117-1125. doi:10.1002/ijc.23613
19. Qiu XQ, Chen G, Yu HP, Hu L (2009) Detection of RASSF1A promoter hypermethylation in plasma of patients with primary hepatocellular carcinoma and its clinical significance. World Chin J Digestol 17:90-93
20. Vivekanandan P, Torbenson M (2008) Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol 21:670-675. doi:10.1038/modpathol.2008.32 (Pubitemid 351744831)
21. Stang A (2010) Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605. doi:10.1007/s10654-010-9491-z
22. Zintzaras E, Ioannidis JP (2005) HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 21:3672-3673. doi:10.1093/bioinformatics/ bti536 (Pubitemid 41264106)
23. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2006) Comparison of two methods to detect publication bias in metaanalysis. JAMA 295:676-680. doi:10.1001/jama.295.6.676 (Pubitemid 43209069)
24. Chen WS, Guo SL (2011) Methylation status of RASSF1 gene promoter in primary hepatocellular carcinoma and its clinical applications. China J Mod Med 21:1864-1867
25. Chen TG, Li JG, Lin ZC (2013) Promoter methylation of RASSF1A gene in hepatocellular carcinoma and its clinical significance. Chin J Gen Surg 28:300-303. doi:10.3760/cma.j.issn.1007-631X.2013.04.016
26. Fei BJ, Huang ZH, Hua D, Hu Y, Chen ZH, Yu J (2011) Clinical significance of methylation of plasma Ras-association domain family 1A gene in the molecular diagnosis of hepatocellular carcinoma. Tumor 31:742-747
27. Zhang YY, Jiang Q, Chen SQ, Gu RM, Zhang XM, Zhu M, Ma GJ (2013) Effects of DNA methylation and micronucleus formation on pathogenesis of hepatocellular carcinoma by methylation-specific polymerase chain reaction and microscopy. Chin J Biomed End 19:11-15. doi:10.3760/cma.j.issn.1674-1927.2013.01.003
28. Zhao QZ, Qi ZF, Wei WL, Li KZ, Dou KF (2006) Diagnostic value of detection of aberrantly methylated RASSF1A in plasma of patients with hepatocellular carcinoma. J Fourth Mil Med Univ 27:1577-1579
29. He QF, Yan D, Wang LX (2010) Promoter hypermethylation of RASSF1A and p16 gene in plasma of patients with hepatocellular carcinoma. Chin J Public Health 26:819-821
30. Gong HY, Liu ZG, Zhang HY (2011) Detection of promoter hypermethylation of RASSF1A and CDH13 gene by nested methylation specific polymerase chain reaction in hepatocellular carcinoma patients. Life Sci Res 15:56-60
31. Zhang X, Li HM, Liu Z, Zhou G, Zhang Q, Zhang T, Zhang J, Zhang C (2013) Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J Gastroenterol 48:132-143. doi:10.1007/s00535-012-0621-0
32. Zhang YJ, Wu HC, Shen J, Ahsan H, Tsai WY, Yang HI, Wang LY, Chen SY et al (2007) Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 13:2378-2384. doi:10.1158/1078-0432. ccr-06-1900 (Pubitemid 46698587)
33. Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ (2005) High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 25:266-272. doi:10.1111/j.1478-3231.2005. 01084.x
34. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R (2003) Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 22:1866-1871. doi:10.1038/sj.onc.1206338 (Pubitemid 36513145)
35. Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM (2012) Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis c? Arab J Gastroenterol 13:111-115. doi:10.1016/j.ajg.2012.06.009
36. Lou C, Du Z, Yang B, Gao Y, Wang Y, Fang S (2009) Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci 100:996-1004. doi:10.1111/j.1349-7006.2009.01138.x
37. Feng Y, Xue WJ, Li P, Sha ZY, Huang H, Rui L, Li HX, Mao QS (2012) Rassf1a hypermethylation is associated with aflatoxin b1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma. Hepatogastroenterology 59:1883-1888. doi:10.5754/hge11731
38. Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW, Lo YM (2008) Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 54:1528-1536. doi:10.1373/clinchem.2008. 104653
39. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS (2006) Ubiquitous activation of ras and jak/stat pathways in human hcc. Gastroenterology 130:1117-1128. doi:10.1053/j.gastro.2006.01.006
40. Tischoff I, Markwarth A, Witzigmann H, Uhlmann D, Hauss J, Mirmohammadsadegh A, Wittekind C, Hengge UR et al (2005) Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int J Cancer 115:684-689. doi:10.1002/ijc.20944 (Pubitemid 40776690)
41. Richter AM, Schagdarsurengin U, Rastetter M, Steinmann K, Dammann RH (2010) Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at serine 203 and regulation of RASSF1A function. Eur J Cancer 46:2986-2995. doi:10.1016/j.ejca.2010.06.128
42. Tian Y, Hou Y, Zhou X, Cheng H, Zhou R (2011) Tumor suppressor rassf1a promoter: P53 binding and methylation. PLoS One 6:e17017. doi:10.1371/journal. pone.0017017
43. Bayram S (2012) RASSF1A ALA133SER polymorphism is associated with increased susceptibility to hepatocellular carcinoma in a Turkish population. Gene 498:264-269. doi:10.1016/j.gene.2012.02.040